
## AIH SUPPORT 

## TRUSTEES’ ANNUAL REPORT AND ACCOUNTS 

Period 1 October 2022 – 30 September 2023 

Registered charity No: 1171952 



## Statutory Informaton 

Regulator: 

Charity Commission for England & Wales 

## Registered Charity Number: 

1171952 

Registered address: 

Crispin Cottage 21 Marksbury BATH BA2 9HS 

## Trustees: 

Ann Brownlee Maeve Hodgins Anne-Marie Nelson Helen Orme 

The trustees were appointed on 8 March 2017 and remained in office throughout the accounting period. No other person served as a trustee in the period. 

## Background 

AIH Support became a registered charity (charity number 1171952) under a CIO Foundation Constitution on 8 March 2017. It is a volunteer led and run charity with no employees. All decisions are made by the trustees. 

## Objectves and Actvites 

The objectives of AIH Support are the relief of sickness and the promotion of good health among those suffering from the liver condition known as autoimmune hepatitis (AIH). 

This will be achieved by providing information, advice and support to patients, carers, health professionals and the public generally. In addition, AIH Support supports and encourages research into AIH. 

2 



## Summary of Actvites 

We have continued to support those affected by autoimmune hepatitis (AIH). 

Our main area of activity has been our Facebook group. This has now grown to over 4,000 members and roughly 30,000 comments to posts a year. Questions cover all aspects of AIH diagnosis and treatments. 

We held no face to face events in the year although there are plans to hold such an event next year as we feel that concerns over Covid have reduced to a level to make that possible. We are also exploring how best to offer information via video. 

Fund raising remains low after the pandemic but we have been able to manage expenditure to cope. Gift Aid has been claimed on relevant donations. 

We continue to represent AIH patients in dealings with researchers supporting one grant application in the year. This support included identifying patients to talk to the researcher and discuss the proposed study so that patient views were taken into account in the study design. 

We are also continue to represent patients on work to develop new UK treatment guidelines for AIH and publication is imminent. 

## Accounts 

Receipts and payment accounts have been prepared and are attached. Net receipts in the period were £414. 

## Reserves Policy 

Reserves of 6 months expenditure will be maintained going forward and this policy will be assessed on an annual basis. 

In accordance with the Charitable Incorporated Organisation (General) Regulations 2012 the two following points are made: 

## Guarantees 

No guarantees have been given by AIH Support where any potential liability under the guarantee is outstanding at 30 September 2022. 

3 



## Debts 

There are no debts outstanding at 30 September 2022 owed by AIH Support or secured by an express charge on any of the assets of the CIO. 

## Public beneft 

The trustees confirm that they have had due regard to the published Charity Commission guidance on public benefit in exercising their powers or duties. 

## Future Plans 

A face to face event is planned for next year. We will continue to encourage research by providing the patient perspective and priorities to researchers and clinicians. 

After the year end we began the process of moving to new bankers. 

The trustees approved this report on 

Signed 

Date 


16 May 2024 

A Brownlee on behalf of Trustees 

4 




**Charity Name No (if any) AIH SUPPORT 1171952** 

## **Receipts and payments accounts** 

**CC16a** 

**For the period** 1-Oct-22 30-Sep-23 **To from** 

|**Section A Receipts and payments**|**Section A Receipts and payments**|||||
|---|---|---|---|---|---|
|**A1 Receipts**<br>Donations<br>**699**<br>Advice Service Fees<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**699**<br>**Unrestricted**<br>**funds**<br>**to the nearest      £**<br>**_Sub total_**_(Gross income for AR)_||**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Restricted**<br>**funds**|**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Endowment**<br>**funds**|**Total funds**<br>**to the nearest £**<br>**699**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**699**|**Last year**<br>**to the nearest £**|
|Donations|**699**|**-**|**-**|**699**|**1,133**|
|Advice Service Fees|**-**|**-**|**-**|**-**|**-**|
||**-**|**-**|**-**|**-**|**-**|
||**-**|**-**|**-**|**-**|**-**|
||**-**|**-**|**-**|**-**|**-**|
||**-**|**-**|**-**|**-**|**-**|
||**-**|**-**|**-**|**-**|**-**|
||**-**|**-**|**-**|**-**|**-**|
|**_Sub total_**_(Gross income for AR)_|**699**<br>|**-**|**-**|**699**|**1,133**|
|**-**<br>**-**<br>**_Sub total_                             -**<br>**_Total receipts_                       699**<br>**A2 Asset and investment sales,**<br>**(see table).**||**-**<br>**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**<br>**699**||
|||||||
||||||**-**|
||||||**-**|
|||||||
|||**-**|**-**|**699**|**1,133**|



|**A2 Asset and investment sales,**||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|**(see table).**||||||||||||
|||**-**||**-**||**-**||**-**||||
|||**-**||**-**||**-**||**-**||**-**||
|**_Sub total_**||**-**||**-**||**-**||**-**||**-**||
|||||||||||||
|**_Total receipts_ **||**699**||**-**||**-**||**699**||**1,133**||



|**A3 Payments**<br>FundraisingCosts<br>**-**<br>Cost of Activities<br>**285**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**_Sub total_                          285**<br>**-**<br>**-**<br>**_Sub total_                              -**<br>**_Total payments_                       285**<br>**_Net of receipts/(payments)_                       414**<br>**A5 Transfers between funds**<br>**-**<br>**A6 Cash funds last year end**<br>**10,019**<br>**_Cash funds this year end_                  10,433**<br>**A4 Asset and investment**<br>**purchases, (see table)**|**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**-**<br>**285**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**285**<br>**-**<br>**-**<br>**-**<br>**285**<br>**414**<br>**-**<br>**10,019**<br>**10,433**||
|---|---|---|---|---|
|||||**-**|
|||||**284**|
|||||**-**|
|||||**-**|
|||||**-**|
|||||**-**|
|||||**-**|
|||||**-**|
|||||**-**|
|||||**284**|
||||||
||||||
||||||
|||||**-**|
||||||
|||||**284**|
||||||
||**-**|**-**|**414**|**849**|
||**-**|**-**|**-**|**-**|
||**-**|**-**|**10,019**|**9,170**|
||**-**|**-**|**10,433**|**10,019**|



## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>**unds**|**Details**<br>Bank|**to nearest £**<br>**10,433**<br>**Unrestricted**<br>**funds**|**to nearest £**<br>**-**<br>**Restricted**<br>**funds**|**to nearest £**<br>**Endowment**<br>**funds**|
|---|---|---|---|---|
||Bank|**10,433**|**-**|**-**|



**B1 Cash funds** 



## **B2 Other monetary assets** 

## **B3 Investment assets** 

**B4 Assets retained for the charity’s own use** 

## **B5 Liabilities** 

Signed by one or two trustees on behalf of all the trustees 

|||**-**|||**-**||**-**||
|---|---|---|---|---|---|---|---|---|
|||**-**|||**-**||**-**||
|**_Total cash funds_**||**10,433**|||**-**||**-**||
|(agree balances with receipts and payments<br>account(s))||OK||OK|||OK||
|||**Unrestricted**||**Restricted**|||**Endowment**||
|||**funds**||**funds**|||**funds**||
|**Details**||**to nearest £**||**to nearest £**|||**to nearest £**||
|||**-**|||**-**||**-**||
|||**-**|||**-**||**-**||
|||**-**|||**-**||**-**||
|||**-**|||**-**||**-**||
|||**-**|||**-**||**-**||
|||**-**|||**-**||**-**||



|**Details**<br>**Details**<br>**Details**<br>Signature|**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>ANN BROWNLEE<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**|**Current value**<br>**(optional)**|
|---|---|---|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**Current value**<br>**(optional)**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**When due**<br>**(optional)**|
||||
||||
||||
||||
||||
||||
|||Date of<br>approval|
||ANN BROWNLEE|16-May-24|
||||



